Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia

Keryx Biopharmaceuticals (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced the publication of a post-hoc analysis of Auryxia phase 3 trial data for iron deficiency anemia in adult patients with chronic kidney disease (CKD), not on dialysis, in the online issue of the American Journal of Hematology.

As quoted in the press release:

“While patients with lower baseline measures of TSAT/ferritin values experienced a greater hemoglobin increase than those with higher baseline measures of iron storage, hemoglobin increases were also clinically significant among those with higher baseline TSAT/ferritin values, indicating that Auryxia is efficacious over a wide range of patients with CKD, not on dialysis,” said John Neylan, M.D., chief medical officer of Keryx Biopharmaceuticals. “These findings support the current KDIGO treatment guidelines that recommend a trial of oral iron in patients with iron deficiency anemia and chronic kidney disease.”

Click here to read the full press release.